RespireRx Pharmaceuticals Inc (RSPI): There is no IV formulation of 717 yet ac...

Send PM Follow Ignore

Re: Market_Fest4 post# 14335

Wednesday, 12/05/2007 9:18:14 AM

Wednesday, December 05, 2007 9:18:14 AM

There is no IV formulation of 717 yet according to Stoll. He estimates the market for RD to be 500 million to 1 billion a year.

Keep Last Read

Replies (1) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM

InvestorsHub NewsWire

Only $200 per official company press release!